Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04929223 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
A Phase 1 study of Metastatic Colorectal Cancer, sponsored by Hoffmann-La Roche.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 542
- Enrollment target
- 20
- Study locations
NCT04929223: Recruiting Phase 1 study of Metastatic Colorectal Cancer, sponsored by Hoffmann-La Roche.
NCT04929223 is a Phase 1 study of Metastatic Colorectal Cancer that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 542 participants, above the 174-participant average among 45 other Metastatic Colorectal Cancer trials with a reported enrollment target (211% higher). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04929223, a Phase 1 study of Metastatic Colorectal Cancer, is actively recruiting participants, sponsored by Hoffmann-La Roche.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 542 participants
- Enrollment target
- 20
- Study locations
Study Summary
This open-label, exploratory study is designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or combinations, in participants with metastatic colorectal cancer (mCRC) whose tumors are biomarker positive as per treatment arm-specific definition. Eligible participants with mCRC will be enrolled into specific treatment arms based on their biomarker assay results.
Primary Outcome
Defined as the proportion of participants with a complete response or partial response, as determined by the investigator according to RECIST v1.1
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Atezolizumab
- DRUG Cetuximab
- DRUG Inavolisib
- DRUG Tiragolumab
Study Locations (20)
California
- City of Hope Comprehensive Cancer Center - Duarte
- cCare - Encinitas
- USC Norris Cancer Center - Los Angeles
- Cedars-Sinai Medical Center - Los Angeles
- UCLA - Los Angeles
- Hoag Memorial Hospital Presbyterian - Newport Beach
- Stanford Cancer Center - Stanford
Connecticut
- Yale Cancer Center - New Haven
- Eastern Ct Hema/Onco Assoc - Norwich
Florida
- Mayo Clinic in Florida - Jacksonville
- Moffitt Cancer Center - Tampa
New York
- New York Cancer & Blood Specialists - New Hyde Park - New Hyde Park
- New York Cancer and Blood Specialists-Central Park Hematology & Oncology - New York
Alabama
- UAB Comprehensive Cancer Center - Birmingham
Arizona
- Mayo Clinic Arizona - Phoenix
Colorado
- University of Colorado Cancer Center - Aurora
Louisiana
- Mary Bird Perkins Cancer Ctr - Baton Rouge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 542 participants |
| Start Date | 2021-10-22 |
| Est. Completion | 2030-08-31 |
| Phase | Phase 1 |
What NCT04929223 shows while recruiting
NCT04929223 is an interventional study that assigns participants to a tested intervention. The registered 542 participants enrollment target is mid-sized for trials with a published cap, above the 174-participant average among 45 other Metastatic Colorectal Cancer trials with a reported enrollment target (211% higher).
The record links to 1 condition, with Metastatic Colorectal Cancer appearing as the primary indexed condition, and to 5 interventions - of which Bevacizumab is the first listed.
NCT04929223 names 20 study sites across 11 states, led by California, Connecticut, Florida.
Frequently Asked Questions
What is clinical trial NCT04929223 about?
NCT04929223 is a clinical study titled "A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)". This open-label, exploratory study is designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or combinations, in participants with metastatic colorectal cancer (mCRC) whose tumors are biomarker positive as per treatment arm-specific definition. Eligible ...
What is the current status of trial NCT04929223?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 542 participants. The study started on 2021-10-22. Estimated completion is 2030-08-31.
What conditions does trial NCT04929223 study?
This clinical trial studies the following conditions: Metastatic Colorectal Cancer.
What interventions are being tested in trial NCT04929223?
The interventions under investigation include: Bevacizumab (DRUG), Atezolizumab (DRUG), Cetuximab (DRUG), Inavolisib (DRUG), Tiragolumab (DRUG).
Who is sponsoring clinical trial NCT04929223?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04929223 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04929223's enrollment target sits among peer trials
542 3rd of 45 higher than 43 of 45 other Metastatic Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)
RECRUITING · Phase 1
-
Trial of ProAgio in Advanced/Metastatic Colorectal Cancer
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
RECRUITING · Phase 1
-
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05584670 · 542 participants · Phase 1
A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors
- NCT07294053 · 543 participants · NA
Sugary Drink Labeling Study
- NCT03127761 · 544 participants
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma
- NCT04378790 · 544 participants · Phase 3
A Randomized Trial to Evaluate Sequential vs Simultaneous Patching
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI